EMEA-000309-PIP04-17-M02

Key facts

Invented name
RoActemra
Active substance
tocilizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0253/2019
PIP number
EMEA-000309-PIP04-17-M02
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Treatment of cytokine release syndrome associated with chimeric antigen receptor (CAR) T cell therapy
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Roche Registration GmbH

Tel. +41 616879411
E-mail: info.paediatrics@roche.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating